Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
A-Share Information
H-Share Information
2022.05.10
ag真人平台官方：关于对深圳证券交易所2021年年报问询函回复的公告
2022.05.05
DELAY IN DESPATCH OF 2021 ANNUAL REPORT
2022.05.05
2022 FIRST QUARTERLY REPORT
2022.05.05
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
2022.05.05
RESIGNATION OF EXECUTIVE DIRECTOR AND CHANGE OF FINANCIAL CONTROLLER
2022.04.30
第五届董事会第十八次会议决议公告
2022.04.30
关于董事辞职及财务总监变更的公告
2022.04.30
独立董事关于第五届董事会第十八次会议相关事项的独立意见
2022.04.30
2022年一季度报告
2022.04.27
关于举行2021年度网上业绩说明会的公告
第一页
上一页
20
21
22
23
24
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
